Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Locker Felix,

** = Publikationen gelistet in SCI/SSCI/Pubmed

** Brunner, SM; Koller, A; Stockinger, J; Locker, F; Leis, S; Ernst, F; Strasser, P; Brodowicz, B; Ebner, S; Holub, BS; Rauch, I; Graf, K; Lang, R; Kofler, B (2019): Validation of antibody-based tools for galanin research. Peptides. 2019; 120:170009

** Koller, A; Brunner, SM; Bianchini, R; Ramspacher, A; Emberger, M; Locker, F; Schlager, S; Kofler, B (2019): Galanin is a potent modulator of cytokine and chemokine expression in human macrophages. Sci Rep. 2019; 9(1):7237
Open Access Logo

** Locker, F; Leitner, J; Aminzadeh-Gohari, S; Weber, DD; Sanio, P; Koller, A; Feichtinger, RG; Weiss, R; Kofler, B; Lang, R (2019): The Influence of Ketogenic Diets on Psoriasiform-Like Skin Inflammation. J Invest Dermatol. 2019;
Open Access Logo [Article in Press]

** Drexel, M; Locker, F; Kofler, B; Sperk, G (2018): Effects of galanin receptor 2 and receptor 3 knockout in mouse models of acute seizures. Epilepsia 59(11): e166-e171.
Open Access Logo

** Locker, F; Vidali, S; Holub, BS; Stockinger, J; Brunner, SM; Ebner, S; Koller, A; Trost, A; Reitsamer, HA; Schwarzenbacher, D; Lang, R; Kofler, B (2018): Lack of Galanin Receptor 3 Alleviates Psoriasis by Altering Vascularization, Immune Cell Infiltration, and Cytokine Expression. J Invest Dermatol. 2018; 138(1):199-207

** Aminzadeh-Gohari, S; Feichtinger, RG; Vidali, S; Locker, F; Rutherford, T; O"Donnel, M; Stöger-Kleiber, A; Mayr, JA; Sperl, W; Kofler, B (2017): A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget. 2017; 8(39):64728-64744

** Vidali, S; Aminzadeh-Gohari, S; Feichtinger, RG; Vatrinet, R; Koller, A; Locker, F; Rutherford, T; O"Donnell, M; Stöger-Kleiber, A; Lambert, B; Felder, TK; Sperl, W; Kofler, B (2017): The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer"s syndrome. Oncotarget. 2017; 8(34):57201-57215

** Botz, B; Kemény, Á; Brunner, SM; Locker, F; Csepregi, J; Mócsai, A; Pintér, E; McDougall, JJ; Kofler, B; Helyes, Z (2016): Lack of Galanin 3 Receptor Aggravates Murine Autoimmune Arthritis. J Mol Neurosci. 2016; 59(2):260-269

** Koller, A; Rid, R; Beyreis, M; Bianchini, R; Holub, BS; Lang, A; Locker, F; Brodowicz, B; Velickovic, O; Jakab, M; Kerschbaum, H; Önder, K; Kofler, B (2016): In vitro toxicity of the galanin receptor 3 antagonist SNAP 37889. Neuropeptides. 2016; 56:83-88

** Kofler, B; Brunner, S; Koller, A; Wiesmayr, S; Locker, F; Lang, R; Botz, B; Kemény, À; Helyes, Z (2015): Contribution of the galanin system to inflammation. Springerplus. 2015; 4(Suppl 1):L57

** Locker, F; Lang, AA; Koller, A; Lang, R; Bianchini, R; Kofler, B (2015): Galanin modulates human and murine neutrophil activation in vitro. Acta Physiol (Oxf). 2015; 213(3):595-602

** Brunner, SM; Farzi, A; Locker, F; Holub, BS; Drexel, M; Reichmann, F; Lang, AA; Mayr, JA; Vilches, JJ; Navarro, X; Lang, R; Sperk, G; Holzer, P; Kofler, B (2014): GAL3 receptor KO mice exhibit an anxiety-like phenotype. Proc Natl Acad Sci U S A. 2014; 111(19):7138-7143

© Veterinärmedizinische Universität Wien Hilfe und Downloads